Drug pricing

Caravan Health Appoints LeeAnn Scheer as Chief Pharmacy Officer

Retrieved on: 
Thursday, May 20, 2021
Pharmacy, Medicinal chemistry, Symbols, MultiCare Health System, Health Resources and Services Administration, Drug pricing, 340B Drug Pricing Program

b'KANSAS CITY, Mo., May 20, 2021 /PRNewswire-PRWeb/ --Today, Caravan Health announced the hiring of LeeAnn Scheer as Chief Pharmacy Officer.

Key Points: 
  • b'KANSAS CITY, Mo., May 20, 2021 /PRNewswire-PRWeb/ --Today, Caravan Health announced the hiring of LeeAnn Scheer as Chief Pharmacy Officer.
  • Ms. Scheer comes to Caravan with a strong background in helping safety net providers, advocating for rural health, and managing pharmacy supply chains.
  • By participating in 340B, safety net providers can reach more eligible patients and provide more comprehensive services, both of which are critical to succeeding in an ACO.\n"With LeeAnn Scheer on board, Caravan Health is ready to provide more support to our clients in managing their sickest patients," said Tim Gronniger , Caravan Health President and CEO.
  • She joins Caravan from MultiCare Health System, where she served as System Director of Pharmacy Supply Chain and 340B.

340B Program: AHF Salutes Biden Administration for Ordering Six Drug Companies to Restore Price Discounts

Retrieved on: 
Tuesday, May 18, 2021
AIDS, White House, Federal Government, Health, Philanthropy, Healthcare reform, Public policy, Pharmaceutical, Other Policy Issues, Hospitals, Foundation, Public policy, Government, Health Resources and Services Administration, Rockville, Maryland, Presidency of Joe Biden, Drug pricing, 340B Drug Pricing Program

( HRSA press statement on violation letters ).\n"Thousands of non-profit providers depend on the 340B program to keep their doors open to serve vulnerable populations.

Key Points: 
  • ( HRSA press statement on violation letters ).\n"Thousands of non-profit providers depend on the 340B program to keep their doors open to serve vulnerable populations.
  • 340B costs taxpayers nothing and stretches federal programs that strengthen the healthcare safety net, already severely stressed by a system that enriches the for-profit pharmaceutical industry," said Laura Boudreau, Chief of Operations, Risk Management and Quality Improvement for AHF.
  • "We\'re delighted the Biden Administration has shown it will defend the 340B Program that the pharmaceutical industry tries every day to strangle.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005839/en/\n'

Capital Rx and 3 Axis Advisors Study Finds Potential for Billions in Prescription Drug Savings With Transparent Pricing Practices

Retrieved on: 
Tuesday, May 11, 2021
Technology, Insurance, Other Technology, Professional services, Software, Health, Pharmaceutical, Data management, Other Professional Services, Health sciences, Drug pricing, Health, Pharmacy, Symbols, Clinical pharmacology, Pharmaceutical industry, Medication costs, National Average Drug Acquisition Cost, Prescription drug, Medical prescription, Pricing

The full study results are available here .\nPotential legislative changes could expand pharmacies\xe2\x80\x99 retail survey reporting of NADAC.

Key Points: 
  • The full study results are available here .\nPotential legislative changes could expand pharmacies\xe2\x80\x99 retail survey reporting of NADAC.
  • Utilizing NADAC is free on a public website, increasing transparency and visibility into actual average retail drug acquisition price.\nMatthew Gibbs, Pharm.
  • D., President of Commercial Markets at Capital Rx, said, \xe2\x80\x9cThis study clearly shows that greater transparency with prescription drug pricing practices could create billions of dollars in savings for patients and payers.
  • Capital Rx has been utilizing NADAC pricing as a foundation for our Clearinghouse Model for over three years.

Caravan Health Launches 340B Technology Solution to Improve the Strength and Compliance of the Drug Discount Program

Retrieved on: 
Wednesday, May 5, 2021
Healthcare reform in the United States, Health Resources and Services Administration, Drug pricing, Federal assistance in the United States, Liberalism in the United States, Medicare, 340B Drug Pricing Program

Caravan\'s 340B program helps care coordinators learn about these distant visits and manage their subsequent care and prescription medications, improving the quality of patient care and increasing 340B discounts.

Key Points: 
  • Caravan\'s 340B program helps care coordinators learn about these distant visits and manage their subsequent care and prescription medications, improving the quality of patient care and increasing 340B discounts.
  • Caravan\'s proprietary 340B technology automatically prevents non-compliant referral claims from being validated while capturing the documentation needed to validate eligible prescriptions.
  • Through its program of transparency and mutual accountability, Caravan Health has delivered more than 10 times the national average in real savings since 2015.
  • In 2019 and 2020, Caravan Health partners earned $300 million in Medicare savings, over $120 million in shared savings and earned quality scores exceeding 94%.

Biologic Drug Patent Plan Database Service 2021: US & International Patents, including Active and Expired Patents, Finished Product Suppliers, Manufacturers - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 28, 2021
Health, Pharmaceutical, Pharmacy, Pharmaceutical industry, Life sciences, Drug pricing, Medication costs

b'The "Drug Patent Database Subscription: Biologic Drugs" database has been added to ResearchAndMarkets.com\'s offering.\nThe Biologic Drugs Plan Database helps drug companies make better decisions through the delivery of cutting-edge business intelligence.

Key Points: 
  • b'The "Drug Patent Database Subscription: Biologic Drugs" database has been added to ResearchAndMarkets.com\'s offering.\nThe Biologic Drugs Plan Database helps drug companies make better decisions through the delivery of cutting-edge business intelligence.
  • The Biologic Drug plan is focused on the interests of biotechnology drug manufacturers, suppliers, distributors, and payers.\nThe researcher is a provider of global business intelligence on biologic and small-molecule drugs, dedicated to helping clients make better decisions.
  • Critical information on global drug patents is incorporated with litigation intelligence, drug prices, and historic sales figures to help users discover commercial opportunities and forecast future revenue events.
  • This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches.

Increased Innovation and Adoption of Interoperable Technology Accelerated the Digital Transformation of Healthcare in 2020

Retrieved on: 
Tuesday, April 20, 2021
Technology, Mobile, Wireless, Software, Practice Management, Networks, Health, Pharmaceutical, General Health, Data management, Medicinal chemistry, Pharmacy, Symbols, Articles, Pharmaceuticals policy, Applied sciences, Drug pricing

b'In the face of the COVID-19 pandemic, the digital transformation of healthcare accelerated in 2020 with increased adoption of interoperable tools to support innovations in care management, price transparency and specialty medications, according to the Surescripts 2020 National Progress Report .

Key Points: 
  • b'In the face of the COVID-19 pandemic, the digital transformation of healthcare accelerated in 2020 with increased adoption of interoperable tools to support innovations in care management, price transparency and specialty medications, according to the Surescripts 2020 National Progress Report .
  • Surescripts initiated efforts to eliminate duplicate messages and medications, reducing the number of Medication History messages delivered from 2.18 billion in 2019 to 1.95 billion in 2020.
  • And together with pharmacies, health systems and technology vendors, Surescripts improved its network-wide Quality Index Score for e-prescription accuracy by 11%.\nDownload the Surescripts 2020 National Progress Report to learn more about how technology is transforming healthcare.
  • Visit us at surescripts.com and follow us at twitter.com/surescripts .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005092/en/\n'

Kalderos' 2021 annual report sets a vision for tech-enabled, patient-centered solutions in Drug Discount Management

Retrieved on: 
Tuesday, April 20, 2021
Drug pricing, Health Resources and Services Administration, 340B Drug Pricing Program

b'CHICAGO, April 20, 2021 /PRNewswire/ -- Innovative tech company Kalderos today released its 2021 annual report.

Key Points: 
  • b'CHICAGO, April 20, 2021 /PRNewswire/ -- Innovative tech company Kalderos today released its 2021 annual report.
  • During this pivotal moment, it\'s the perfect time to launch our inaugural annual report.
  • More than half of all hospitals who participate in the 340B program now use Kalderos\' provider-facing Discount Monitoring tool.
  • The company\'s product roadmap includes an expansion into data-driven, transparency-minded platform solutions for other drug discount programs.\nTitled "Making health policy work for patients: how platform solutions enable more affordable drugs," the 2021 annual report is freely available to download now .\nKalderos created the world\'s first Drug Discount Management platform, which uses sophisticated models and machine learning to resolve noncompliance in drug discount programs.

The inaugural annual report from Kalderos, a healthcare technology startup, includes data-driven insights on systemic inefficiencies in the drug distribution system and charts the company's rapid growth

Retrieved on: 
Tuesday, April 20, 2021
Drug pricing, Health Resources and Services Administration, 340B Drug Pricing Program

b'CHICAGO, April 20, 2021 /PRNewswire/ --Innovative tech company Kalderos today released its 2021 annual report.

Key Points: 
  • b'CHICAGO, April 20, 2021 /PRNewswire/ --Innovative tech company Kalderos today released its 2021 annual report.
  • "Industry trends are driving change and so is the massive impact of COVID-19.
  • During this pivotal moment, it\'s the perfect time to launch our inaugural annual report.
  • More than half of all hospitals who participate in the 340B program now use Kalderos\' provider-facing Discount Monitoring tool.

Government of Canada establishes Critical Drug Reserve to bolster Canada's supply of drugs used to treat COVID-19

Retrieved on: 
Wednesday, April 14, 2021
Health sciences, Pharmacy, Pharmaceutical sciences, Health care, Pharmaceutical industry, Pharmacology, Drugs, Drug pricing, Pharmaceuticals policy

The reserve targets the drugs that hospitals rely on most to treat patients who are critically ill with COVID-19, and are at risk of shortage.

Key Points: 
  • The reserve targets the drugs that hospitals rely on most to treat patients who are critically ill with COVID-19, and are at risk of shortage.
  • The Critical Drug Reserve complements these efforts by providing a safety net of increased supply of key drugs used in the treatment of COVID-19.
  • "\nAs of early April 2021, the Government of Canada has awarded more than $26 million in contracts to Canadian pharmaceutical companies for drugs in the Critical Drug Reserve that will be cost-shared with participating provinces and territories.\nParticipation in the Critical Drug Reserve is voluntary.
  • This includes four Interim Orders to prevent or alleviate the effects of shortages and to safeguard supply:\n'

Consumers In Pain Over High Prescription Prices, Ready To Take Action And In Need Of Better Tools, According To Survey By Scripta Insights

Retrieved on: 
Wednesday, April 14, 2021
Health sciences, Health, Clinical pharmacology, Pharmacy, Pharmaceuticals policy, Pharmaceutical industry, Drug pricing, Prescription drug, Medical prescription, Medication costs

So, it\'s not surprising that "Expensive, Necessary and Cost(ly)" are the first three words that come to mind when people think about prescription drugs.

Key Points: 
  • So, it\'s not surprising that "Expensive, Necessary and Cost(ly)" are the first three words that come to mind when people think about prescription drugs.
  • People believe pharma companies are the number one offender (52%) most to blame for high prescription drug prices, followed by insurance companies (17%) and the government (15%).
  • At Scripta, we provide our members with the information they need to be better prescription shoppers and have more informed conversations with their doctor.
  • Scripta reviews each member\'s recent prescriptions, analyzes them using their exclusive savings database, and finds savings opportunities.